275 related articles for article (PubMed ID: 15353488)
21. Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice.
Shah PK; Nilsson J; Kaul S; Fishbein MC; Ageland H; Hamsten A; Johansson J; Karpe F; Cercek B
Circulation; 1998 Mar; 97(8):780-5. PubMed ID: 9498542
[TBL] [Abstract][Full Text] [Related]
22. Human apolipoprotein A-IV reduces secretion of proinflammatory cytokines and atherosclerotic effects of a chronic infection mimicked by lipopolysaccharide.
Recalde D; Ostos MA; Badell E; Garcia-Otin AL; Pidoux J; Castro G; Zakin MM; Scott-Algara D
Arterioscler Thromb Vasc Biol; 2004 Apr; 24(4):756-61. PubMed ID: 14751811
[TBL] [Abstract][Full Text] [Related]
23. Murine cytomegalovirus infection increases aortic expression of proatherosclerotic genes.
Burnett MS; Durrani S; Stabile E; Saji M; Lee CW; Kinnaird TD; Hoffman EP; Epstein SE
Circulation; 2004 Feb; 109(7):893-7. PubMed ID: 14757699
[TBL] [Abstract][Full Text] [Related]
24. Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth.
Luttun A; Lutgens E; Manderveld A; Maris K; Collen D; Carmeliet P; Moons L
Circulation; 2004 Mar; 109(11):1408-14. PubMed ID: 14993123
[TBL] [Abstract][Full Text] [Related]
25. Interleukin-1 receptor signaling mediates atherosclerosis associated with bacterial exposure and/or a high-fat diet in a murine apolipoprotein E heterozygote model: pharmacotherapeutic implications.
Chi H; Messas E; Levine RA; Graves DT; Amar S
Circulation; 2004 Sep; 110(12):1678-85. PubMed ID: 15353494
[TBL] [Abstract][Full Text] [Related]
26. 4F Peptide reduces nascent atherosclerosis and induces natural antibody production in apolipoprotein E-null mice.
Wool GD; Cabana VG; Lukens J; Shaw PX; Binder CJ; Witztum JL; Reardon CA; Getz GS
FASEB J; 2011 Jan; 25(1):290-300. PubMed ID: 20876212
[TBL] [Abstract][Full Text] [Related]
27. Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery.
Eitzman DT; Westrick RJ; Xu Z; Tyson J; Ginsburg D
Blood; 2000 Dec; 96(13):4212-5. PubMed ID: 11110693
[TBL] [Abstract][Full Text] [Related]
28. Loss of one copy of Zfp148 reduces lesional macrophage proliferation and atherosclerosis in mice by activating p53.
Sayin VI; Khan OM; Pehlivanoglu LE; Staffas A; Ibrahim MX; Asplund A; Agren P; Nilton A; Bergström G; Bergo MO; Borén J; Lindahl P
Circ Res; 2014 Oct; 115(9):781-9. PubMed ID: 25212213
[TBL] [Abstract][Full Text] [Related]
29. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice.
Navab M; Anantharamaiah GM; Reddy ST; Hama S; Hough G; Grijalva VR; Wagner AC; Frank JS; Datta G; Garber D; Fogelman AM
Circulation; 2004 Jun; 109(25):3215-20. PubMed ID: 15197147
[TBL] [Abstract][Full Text] [Related]
30. Retardation of atherosclerosis by overexpression of catalase or both Cu/Zn-superoxide dismutase and catalase in mice lacking apolipoprotein E.
Yang H; Roberts LJ; Shi MJ; Zhou LC; Ballard BR; Richardson A; Guo ZM
Circ Res; 2004 Nov; 95(11):1075-81. PubMed ID: 15528470
[TBL] [Abstract][Full Text] [Related]
31. Oral synthetic phospholipid (DMPC) raises high-density lipoprotein cholesterol levels, improves high-density lipoprotein function, and markedly reduces atherosclerosis in apolipoprotein E-null mice.
Navab M; Hama S; Hough G; Fogelman AM
Circulation; 2003 Oct; 108(14):1735-9. PubMed ID: 14504179
[TBL] [Abstract][Full Text] [Related]
32. Genetic ablation of caveolin-1 confers protection against atherosclerosis.
Frank PG; Lee H; Park DS; Tandon NN; Scherer PE; Lisanti MP
Arterioscler Thromb Vasc Biol; 2004 Jan; 24(1):98-105. PubMed ID: 14563650
[TBL] [Abstract][Full Text] [Related]
33. Association of multiple cellular stress pathways with accelerated atherosclerosis in hyperhomocysteinemic apolipoprotein E-deficient mice.
Zhou J; Werstuck GH; Lhoták S; de Koning AB; Sood SK; Hossain GS; Møller J; Ritskes-Hoitinga M; Falk E; Dayal S; Lentz SR; Austin RC
Circulation; 2004 Jul; 110(2):207-13. PubMed ID: 15210586
[TBL] [Abstract][Full Text] [Related]
34. Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice.
Bellosta S; Mahley RW; Sanan DA; Murata J; Newland DL; Taylor JM; Pitas RE
J Clin Invest; 1995 Nov; 96(5):2170-9. PubMed ID: 7593602
[TBL] [Abstract][Full Text] [Related]
35. High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization.
Shah PK; Yano J; Reyes O; Chyu KY; Kaul S; Bisgaier CL; Drake S; Cercek B
Circulation; 2001 Jun; 103(25):3047-50. PubMed ID: 11425766
[TBL] [Abstract][Full Text] [Related]
36. Effect of treatment with human apolipoprotein A-I on atherosclerosis in uremic apolipoprotein-E deficient mice.
Pedersen TX; Bro S; Andersen MH; Etzerodt M; Jauhiainen M; Moestrup S; Nielsen LB
Atherosclerosis; 2009 Feb; 202(2):372-81. PubMed ID: 18489910
[TBL] [Abstract][Full Text] [Related]
37. Comparative Effects of Diet-Induced Lipid Lowering Versus Lipid Lowering Along With Apo A-I Milano Gene Therapy on Regression of Atherosclerosis.
Wang L; Tian F; Arias A; Yang M; Sharifi BG; Shah PK
J Cardiovasc Pharmacol Ther; 2016 May; 21(3):320-8. PubMed ID: 26499098
[TBL] [Abstract][Full Text] [Related]
38. APOA-1Milano muteins, orally delivered via genetically modified rice, show anti-atherogenic and anti-inflammatory properties in vitro and in Apoe
Romano G; Reggi S; Kutryb-Zajac B; Facoetti A; Chisci E; Pettinato M; Giuffrè MR; Vecchio F; Leoni S; De Giorgi M; Avezza F; Cadamuro M; Crippa L; Leone BE; Lavitrano M; Rivolta I; Barisani D; Smolenski RT; Giovannoni R
Int J Cardiol; 2018 Nov; 271():233-239. PubMed ID: 29907443
[TBL] [Abstract][Full Text] [Related]
39. Deficiency in lymphotoxin β receptor protects from atherosclerosis in apoE-deficient mice.
Grandoch M; Feldmann K; Göthert JR; Dick LS; Homann S; Klatt C; Bayer JK; Waldheim JN; Rabausch B; Nagy N; Oberhuber A; Deenen R; Köhrer K; Lehr S; Homey B; Pfeffer K; Fischer JW
Circ Res; 2015 Apr; 116(8):e57-68. PubMed ID: 25740843
[TBL] [Abstract][Full Text] [Related]
40. Direct effect of an acyl-CoA:cholesterol acyltransferase inhibitor, F-1394, on atherosclerosis in apolipoprotein E and low density lipoprotein receptor double knockout mice.
Chiwata T; Aragane K; Fujinami K; Kojima K; Ishibashi S; Yamada N; Kusunoki J
Br J Pharmacol; 2001 Aug; 133(7):1005-12. PubMed ID: 11487509
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
